News Boehringer announces IPF deal with Korea's Bridge Biotherape... Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).
Partner Content Partner Content Three Interactive Sessions to take place at the Respiratory ... Interactive Sessions at RDD
Partner Content Partner Content Registration is Live for the Inaugural Respiratory Drug Deli... Registration is Live for the Inaugural Respiratory Drug
Views & Analysis Propeller Health: respiring for success David Van Sickle is on a mission to transform treatment for respiratory diseases with the company he co-founded, Propeller Health.
Events Partner Content SMi’s Inaugural Conference: Respiratory Drug Delivery 2019 Respiratory Drug Delivery Conference 2019
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.